Stabilized factor ix formulations containing trehalose
OwnerSamia Mankarious, Michael J. Griffithinventors
Life of this patent
Estimating the term…
Loading patent…
OwnerSamia Mankarious, Michael J. Griffithinventors
Estimating the term…
Methods of preparing lyophilized preparations of Factor IX which preserve more than 90% of the calcium binding property of Factor IX are disclosed. Factor IX formulated with trehalose shows a superior stability profile after 12 weeks storage at 25° C./60% relative humidity (RH) and 40° C./75% RH relative to Factor IX formulated without trehalose. The data suggest that the inclusion of trehalose in the formulation could allow for temperature excursions or even long-term room temperature storage of a Factor IX lyophilized product. The formulations tested contained 10 mM histidine pH 6.8, 3% mannitol, 66 mM sodium chloride, 0.0075% Polysorbate 80, with and without 1% trehalose. Upon storage at 40° C./75% RH or 25° C./60% RH over 12 weeks the trehalose-containing formulation was comparable to product stored at 2-8° C. while the formulation without trehalose was found to undergo significant aggregation and loss of activity. The two formulations demonstrated comparable stability over 26 weeks of real time storage at −20° C. and 2-8° C.
A lyophilized composition comprising Factor IX and trehalose, wherein the trehalose is present in an amount from 0.5 to 3% by volume.
(canceled)
A method for preparing a composition of Factor IX, comprising:
(canceled)
-19. (canceled)
Dependencies are inferred from the claim text.